Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 20/20 | 0.61 |
| ▸ | FLT4 | P35916 | 20/20 | 0.61 |
| ▸ | KDR | P35968 | 20/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tasisulam SCHEMBL1581371 | 0.99 | FLT1 (0.62) | FLT1FLT4KDR | |
| Tasisulam SCHEMBL29376914 | 0.99 | FLT1 (0.62) | FLT1FLT4KDR | |
| SCHEMBL5514080 | 0.88 | FLT1 (0.62) | FLT1FLT4KDR | |
| SCHEMBL5966429 | 0.88 | FLT1 (0.65) | FLT1FLT4KDR | |
| SCHEMBL5966464 | 0.86 | FLT1 (0.53) | FLT1FLT4KDR | |
| SCHEMBL5966441 | 0.86 | FLT1 (0.62) | FLT1FLT4KDR | |
| SCHEMBL5966461 | 0.86 | FLT1 (0.57) | FLT1FLT4KDR | |
| SCHEMBL5966505 | 0.85 | FLT1 (0.63) | FLT1FLT4KDR | |
| SCHEMBL5966433 | 0.83 | FLT1 (0.62) | FLT1FLT4KDR | |
| SCHEMBL21741575 | 0.83 | FLT1 (0.60) | FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250430-B2 | Thiophene-and thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | claimed |
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA S | 2006-10-05 | — | — | US | claimed |
| EP-1442030-B1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | LILLY CO ELI (US) | 2006-08-30 | — | — | EP | claimed |
| US-7084170-B2 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2006-08-01 | — | — | US | claimed |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA SUE (US) | 2004-10-07 | — | — | US | claimed |
| EP-1442030-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2004-08-04 | — | — | EP | claimed |
| WO-2003035629-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2003-05-01 | — | — | WO | claimed |
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2491032-A1 | AKT INHIBITORS | Eli Lilly and Company (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2358710-B1 | AKT AND P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012052757-A1 | TUMOUR PHENOTYPE PATIENT SELECTION METHOD | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | WO | disclosed |
| US-7250430-B2 | Thiophene-and thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA S | 2006-10-05 | — | — | US | disclosed |
| EP-1442030-B1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | LILLY CO ELI (US) | 2006-08-30 | — | — | EP | disclosed |
| US-7084170-B2 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA SUE (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1442030-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003035629-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149684-A1 | AKT INHIBITORS | AKT2, PIK3CA, AKT3 | FLT1 1102/4885FLT4 1488/4885KDR 1567/4885 |
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | TPMT, TST, MGMT | FLT1 2922/4885FLT4 2768/4885KDR 4359/4885 |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ALDH1A2, MGMT, NR2E3 | FLT1 206/4885FLT4 444/4885KDR 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.